Public Board of Directors papers 241122

Opened out for any questions. No comments or questions raised. Noted

35/22 Key Reports a Trust report

RS informed the Board that on 12 th October CQC began their review as part of a routine inspection process. CQC have given a schedule of 15 th -17 th November for the well-led inspection part of the review and a number of colleagues will be engaged as part of the process. The designation of Manchester as a Biomedical Research Centre with an award of £59.1 million has been announced which is double the original award value, a large proportion is in relation to cancer. Living with and beyond cancer is a new theme as part of the new programme for the centre. NHS England (NSHE) have released its new operating framework that the Trust needs to become familiar with. Further information has just come through on the required changes to provider licence terms, this will come back to the Board in RA asked on the doubling of the award to GM for the Biomedical Research Centre and if this also equates to a doubling of the cancer research fund. RS stated there were originally 7 themes with just over half related to cancer, this is now nearer to 12, the scope and volume for each theme is different so may increase the amount of funding into cancer themes but won’t be double. FB added that there have also been increases to funding to partners elsewhere within the North West. GP asked if any practical changes for the Trust and if there are any challenges. FB stated that existing researchers will continue to be funded with a bit more money for other research work. A few posts may be able to be recruited to along with posts within the science labs. Can provide further details as things develop. NB added that it is a real opportunity in relation to living with and beyond cancer. No further comments or questions raised. Noted b Integrated performance, quality & finance report BD outlined the September performance. There have been no SI incidents, never events or major incidents. 7 moderate incidents and 5 sepsis 1-hour breaches, there is an action plan associated with this. There were 6 cases of C.diff with no lapses in care, 5 cases of E-Coli post 48 hours and 5 Covid nosocomial infections. The number of new complaints has reduced in month with 46 PALS contacts dure course with the changes. Opened out for any questions.

received, LOS at 6.74 and 2 cancelled operations. 5 corporate risks at 15+; 1 at 20, 1 at 16 and 3 at 15.

In terms of things to note for access, 24-day performance is key and this was 82.0%. 31-day performance at 97.4% which is the area for the majority of patients. Referrals within predicted range.

5